Australija - engleski - Department of Health (Therapeutic Goods Administration)

biomarin pharmaceutical australia pty ltd - pegvaliase, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; trometamol; water for injections; trometamol hydrochloride; cinnamic acid - palynziq is indicated for the treatment of patients with phenylketonuria (pku) aged 16 years and older who have inadequate blood phenylalanine control despite prior management with available treatment options.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

biomarin pharmaceutical australia pty ltd - pegvaliase, quantity: 2.5 mg - injection, solution - excipient ingredients: trometamol hydrochloride; trometamol; cinnamic acid; sodium chloride; water for injections - palynziq is indicated for the treatment of patients with phenylketonuria (pku) aged 16 years and older who have inadequate blood phenylalanine control despite prior management with available treatment options.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

biomarin pharmaceutical australia pty ltd - pegvaliase, quantity: 10 mg - injection, solution - excipient ingredients: cinnamic acid; trometamol; sodium chloride; water for injections; trometamol hydrochloride - palynziq is indicated for the treatment of patients with phenylketonuria (pku) aged 16 years and older who have inadequate blood phenylalanine control despite prior management with available treatment options.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - galsulfase 1 mg/ml - concentrate for infusion - 1 mg/ml - active: galsulfase 1 mg/ml excipient: polysorbate 80 sodium chloride sodium phosphate water for injection - naglazyme is indicated as long term enzyme replacement therapy in patients with mucopolysaccharidosis vi (mps vi, n-acetylgalactosamine 4-sulfatase deficiency, maroteaux-lamy syndrome).

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - laronidase 0.58 mg/ml (rch) - concentrate for infusion - 500 u/5ml - active: laronidase 0.58 mg/ml (rch) excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aldurazyme is indicated as long-term enzyme replacement therapy in patients with mucopolysaccharidosis i (mps i; alpha-l-iduronidase deficiency) to treat the non-neurological manifestations of the disease.

Malezija - engleski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharm-d sdn. bhd. - galsulfase -

Izrael - engleski - Ministry of Health

medison pharma ltd - sapropterin dihydrochloride - tablets soluble - sapropterin dihydrochloride 100 mg - sapropterin - sapropterin - kuvan is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment.kuvan is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Izrael - engleski - Ministry of Health

medison pharma ltd - sapropterin dihydrochloride - tablets soluble - sapropterin dihydrochloride 100 mg - sapropterin - kuvan is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment.kuvan is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Izrael - engleski - Ministry of Health

medison pharma ltd - sapropterin dihydrochloride - tablets soluble - sapropterin dihydrochloride 100 mg - sapropterin - kuvan is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment.kuvan is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Malezija - engleski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bio-science marketing sdn. bhd. - omega-3 fish oil; squalene; vitamin e (d-alpha tocopherol) -